Biography
Chris Farina is the Chief Executive Officer of Abcentra. He has been with the team since 2013, and, since joining has been working on the development of orticumab and oxidized LDL inhibition for the treatment of coronary artery disease. Mr. Farina was part of the management team that designed, completed, and reported the results of a phase 2a proof-of-activity with orticumab, which generated the first clinical proof-of-activity evidence supporting the concept of pharmacological inhibition of oxidized LDL. Prior to his current role as CEO, he has held the positions of Chief of Staff, Vice President of Operations, Director of R&D Program Management, and Senior Project Manager. Mr. Farina is an inventor on several patents relating to orticumab, and an author of peer-reviewed publications on Orticumab and oxidized LDL inhibition.
Mr. Farina holds a Master of Science (M.S.) Management of Drug Development and Bachelor of Arts (B.A.) in Communication from the University of Southern California. He also holds a Regulatory Affairs Certification (RAC) from The Regulatory Affairs Professional Society. He was also a certified Emergency Medical Technician (EMT).
